Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 3, 1997, Pages 103-106

  Haliotis, F A ^a   Tzortzinis, A A ^a   Papanastasiou, D A ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Glucose 6 phosphate dehydrogenase deficiency; Mefenamic acid; Paracetamol; Tolfenamic acid

Indexed keywords

ANTIPYRETIC AGENT; BILIRUBIN; TOLFENAMIC ACID;

ADOLESCENT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOCRIT; HEMOLYSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SCHOOL CHILD;

ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY TEMPERATURE; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 0030932307     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bartsokas CS, Schulman JD 1982 Can acetaminophen cause hemolysis in G6PD deficiency? Acta Haematol 67: 228
2. Beutler E 1991 Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 324: 169-174
3. Boletis J, Williams AJ, Shortland JR, Brown CB 1989 Irreversible renal failure following mefenamic acid. Nephron 51: 575-576
4. Chan JC, Lai FM, Critchley JA 1991 A case of Stevens Johnson syndrome, cholestatic hepatitis and haemolytic anaemia associated with use of mefenamic acid. Drug Saf 6: 230-234
5. Goodman Gilman A, Goodman LS, Gilman A 1980 The Pharmacological Basis of Therapeutics 6th edn. MacMillan, New York
6. Itami N, Akutsu Y, Yasoshima K, Tochmary H, Takekoshi Y, Matsumoto S 1990 Progressive renal failure despite discontinuation of mefenamic acid (letter comment). Nephron 54: 281-282
7. Kattamis C, Karambula K, Metaxakou-Mavromati A, Matsaniotis N 1971 G6PD deficiency and age. Lancet 1: 235
8. Keinnpu S, Similä S, Kouvalainen K 1978 Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid. Eur J Clin Pharmacol 13: 331-334
9. Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS 1962 Hemolytic effect of therapeutic drugs: clinical considerations of the primaquine-type hemolysis. JAMA 180: 388-394
10. Keinänen S, Similä S, Kouvalainen K 1978 Oral antipyretic therapy: Evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid. Eur J Clin Pharmacol 13: 331-334
11. Kornberg A, Horecher BL 1955 Glucose-6-phosphate dehydrogenase. In: Colowick SP, Kaplan NO (eds) Methods in Enzymology. Academic Press, New York, pp 323-324
12. Kromann-Andersen H, Konacs I, Pedersen A 1986 Adverse reaction during treatment with non-steroidal anti-inflammatory drugs in Denmark during a 15-year period. Ugeskr Laeger 148: 462-468
13. Shirkey HC 1967 Pediatric Therapy. 2nd edn., Mosby, St Louis
14. Similä S, Kouvalainen K, Keinänen S 1976 Oral antipyretic therapy. Evaluation of ibuprofen. Scand J Rheumatol 5: 81-83
15. Similä S, Kouvalainen K, Keinänen S 1977 Oral antipyretic therapy. Evaluation of mefenamic acid. Arzneimittelforschung 27: 687-688
16. Weiss C, Harris S, Barrow W, Buchanan R 1968 Mefenamic acid - an antipyretic for use in children. J Pediatr 72: 867-870
17. Winder CV, Max I, Scotti L, Scherrer RA, Joups EM, Short FW 1962 Antiinflammatory, antipyretic, antinociceptive properties of N. (2,3-xylyl) anthranilic acid (mefenamic acid). J Pharmacol Exp Ther 138: 405